Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

     
 
Spanish
French
Italian
German
English
Arabic
Location map SiteMap Contact Us
 
     
     
     
     
     
     
   

contaner About Us contaner
Advanced Search
Search
Looking for a product?
News & Events
news

Sandoz acquires EBEWE Pharma specialty generics business, improving access for patients worldwide to injectable cancer drugs.

More...

Currently positive negotiations with some new business partners

More...

Contact US
contact us
Address : Villa 62, 4th Touristic Area, 6 October - Egypt.

Tel : (+202) 38240793 -38240794 -
       (+2) 0122 5913006 - (+2) 0122 5917002

Fax: (+202) 38240795 - (+2) 0122 1933144

E-mail : info@bppharma.net

Feedback
Cerebrolysin ®    
Cerebrolysin is a peptide-based drug that exhibits unique neurotrophic and Neuroprotective activity.
Cerebrolysin is produced by standardized enzymatic breakdown of lipid-free brain proteins.

Approximately 25% of low molecular weight peptides (<10K DA) and 75% are free amino acids, based on free nitrogen content.

The effects of Cerebrolysin have been investigated and confirmed in various cell culture and animal models of neurodegeneration and ischemia Cerebrolysin, is indicated in the management of stroke, dementia nad traumatic brain injury.

Cerebrolysin, protects the nerve cells from the hazards of the ischemic cascade. Cerebrolysin reduces excitotoxic damage, blocks overactivation of calcium-dependent proteases, and scavenges free oxygen radicals. It increases neuronal viability and survival

Clinical trials with Cerebrolysin demonstrate that it is significantly effective in acute stroke and stroke rehabilitation and improves neurological function, global scores, activities of daily living, and cognitive performance.

Trials of Cerebrolysin in stroke encompass more than 1,500 ischemic stroke patients.

during and after ischemic events.

 
     
Cerebrolysin